CN109071455B - 用于调节布鲁顿酪氨酸激酶的化合物及方法 - Google Patents

用于调节布鲁顿酪氨酸激酶的化合物及方法 Download PDF

Info

Publication number
CN109071455B
CN109071455B CN201780028799.7A CN201780028799A CN109071455B CN 109071455 B CN109071455 B CN 109071455B CN 201780028799 A CN201780028799 A CN 201780028799A CN 109071455 B CN109071455 B CN 109071455B
Authority
CN
China
Prior art keywords
unsubstituted
various embodiments
substituted
independently
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780028799.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN109071455A (zh
Inventor
R·哈德逊
A-M·博索莱伊
R·A·米勒
E·弗纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corworth Biopharmaceutical Co ltd
Jiaxing Heji Pharmaceutical Co ltd
Original Assignee
Jiaxing Heji Pharmaceutical Co ltd
Corvus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiaxing Heji Pharmaceutical Co ltd, Corvus Pharmaceuticals Inc filed Critical Jiaxing Heji Pharmaceutical Co ltd
Priority to CN202210903642.7A priority Critical patent/CN115746000A/zh
Publication of CN109071455A publication Critical patent/CN109071455A/zh
Application granted granted Critical
Publication of CN109071455B publication Critical patent/CN109071455B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN201780028799.7A 2016-03-11 2017-03-10 用于调节布鲁顿酪氨酸激酶的化合物及方法 Active CN109071455B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210903642.7A CN115746000A (zh) 2016-03-11 2017-03-10 用于调节布鲁顿酪氨酸激酶的化合物及方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662307399P 2016-03-11 2016-03-11
US62/307,399 2016-03-11
US201662342004P 2016-05-26 2016-05-26
US62/342,004 2016-05-26
PCT/US2017/021966 WO2017156495A1 (en) 2016-03-11 2017-03-10 Compounds and methods for modulating bruton's tyrosine kinase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210903642.7A Division CN115746000A (zh) 2016-03-11 2017-03-10 用于调节布鲁顿酪氨酸激酶的化合物及方法

Publications (2)

Publication Number Publication Date
CN109071455A CN109071455A (zh) 2018-12-21
CN109071455B true CN109071455B (zh) 2022-08-02

Family

ID=59789888

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780028799.7A Active CN109071455B (zh) 2016-03-11 2017-03-10 用于调节布鲁顿酪氨酸激酶的化合物及方法
CN202210903642.7A Pending CN115746000A (zh) 2016-03-11 2017-03-10 用于调节布鲁顿酪氨酸激酶的化合物及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210903642.7A Pending CN115746000A (zh) 2016-03-11 2017-03-10 用于调节布鲁顿酪氨酸激酶的化合物及方法

Country Status (12)

Country Link
US (2) US10870652B2 (https=)
EP (1) EP3426637B1 (https=)
JP (1) JP6972002B2 (https=)
KR (1) KR102416971B1 (https=)
CN (2) CN109071455B (https=)
AU (1) AU2017230098B2 (https=)
ES (1) ES2912465T3 (https=)
IL (1) IL261583A (https=)
MX (1) MX388026B (https=)
PL (1) PL3426637T3 (https=)
WO (1) WO2017156495A1 (https=)
ZA (1) ZA201805951B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102416971B1 (ko) * 2016-03-11 2022-07-04 엔젤 파마슈티칼 컴퍼니, 리미티드 브루톤형 티로신 키나제를 조절하기 위한 화합물 및 방법
JOP20190113A1 (ar) * 2016-11-18 2019-05-15 Biocad Joint Stock Co مثبطات بروتون تيروزين كيناز
KR102627756B1 (ko) * 2017-03-22 2024-01-23 쑤저우 바이지부공 파마수티컬 테크널러지 컴퍼니 리미티드 브루톤 타이로신 키나제 억제제
KR102384924B1 (ko) * 2017-07-12 2022-04-08 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
CN108191871B (zh) * 2018-01-02 2020-02-18 成都倍特药业有限公司 新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用
CN111662232B (zh) * 2019-03-06 2022-08-02 中国科学院上海药物研究所 具有2h-吲唑结构的小分子化合物及其合成和应用
TWI762939B (zh) 2019-05-31 2022-05-01 大陸商海思科醫藥集團股份有限公司 Btk抑制劑環衍生物及其製備方法和藥學上的應用
WO2020252397A1 (en) * 2019-06-12 2020-12-17 Baylor College Of Medicine Small molecule proteolysis-targeting chimeras and methods of use thereof
HUE065965T2 (hu) * 2019-09-26 2024-06-28 Jumbo Drug Bank Co Ltd 4-fluor-1H-pyrazolo[3,4-C]piridin-származékok mint szelektív bruton-tirozinkináz (BTK) inhibitorok a B-sejtes limfóma és autoimmun betegségek kezelésére
CN114437078A (zh) * 2020-11-03 2022-05-06 海思科医药集团股份有限公司 一种降解btk的氘代物及其在医药上的应用
CN117377675A (zh) * 2021-06-01 2024-01-09 正大天晴药业集团股份有限公司 含有并环或螺环的布鲁顿酪氨酸激酶降解剂
WO2023009785A1 (en) * 2021-07-29 2023-02-02 Cedilla Therapeutics, Inc. Tead inhibitors and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1353605A (zh) * 1999-03-26 2002-06-12 欧洲凯尔特股份有限公司 芳基取代的吡唑、咪唑、噁唑、噻唑和吡咯及其应用
CN101370784A (zh) * 2005-12-13 2009-02-18 先灵公司 为胞外信号调节激酶抑制剂的新颖化合物
CN101848909A (zh) * 2006-02-14 2010-09-29 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡咯并[3,2-c]吡啶
CN102159214A (zh) * 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
WO2011099764A2 (en) * 2010-02-09 2011-08-18 Hanmi Holdings Co., Ltd. Novel pyrimidine derivative for inhibiting the growth of cancer cells
CN103857396A (zh) * 2011-07-13 2014-06-11 药品循环公司 布鲁顿酪氨酸激酶抑制剂
CN108349940A (zh) * 2015-10-14 2018-07-31 淄博百极常生制药有限公司 布鲁顿酪氨酸激酶抑制剂
CN109310671A (zh) * 2016-01-21 2019-02-05 淄博百极常生制药有限公司 布鲁顿酪氨酸激酶抑制剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
SE0301906D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
US20120101114A1 (en) * 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
US8633318B2 (en) 2008-09-16 2014-01-21 Proximagen Ltd Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
JP5985658B2 (ja) 2012-01-31 2016-09-06 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． ブルトンチロシンキナーゼ阻害薬としての環状分子
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
US9795604B2 (en) 2013-10-25 2017-10-24 Pharmacyclics Llc Methods of treating and preventing graft versus host disease
WO2015124570A1 (en) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
KR102416971B1 (ko) * 2016-03-11 2022-07-04 엔젤 파마슈티칼 컴퍼니, 리미티드 브루톤형 티로신 키나제를 조절하기 위한 화합물 및 방법

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1353605A (zh) * 1999-03-26 2002-06-12 欧洲凯尔特股份有限公司 芳基取代的吡唑、咪唑、噁唑、噻唑和吡咯及其应用
CN101370784A (zh) * 2005-12-13 2009-02-18 先灵公司 为胞外信号调节激酶抑制剂的新颖化合物
CN101848909A (zh) * 2006-02-14 2010-09-29 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡咯并[3,2-c]吡啶
CN102159214A (zh) * 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
WO2011099764A2 (en) * 2010-02-09 2011-08-18 Hanmi Holdings Co., Ltd. Novel pyrimidine derivative for inhibiting the growth of cancer cells
CN103857396A (zh) * 2011-07-13 2014-06-11 药品循环公司 布鲁顿酪氨酸激酶抑制剂
CN108349940A (zh) * 2015-10-14 2018-07-31 淄博百极常生制药有限公司 布鲁顿酪氨酸激酶抑制剂
CN109310671A (zh) * 2016-01-21 2019-02-05 淄博百极常生制药有限公司 布鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
IL261583A (en) 2018-10-31
KR20180133415A (ko) 2018-12-14
EP3426637B1 (en) 2022-02-09
ZA201805951B (en) 2020-12-23
ES2912465T3 (es) 2022-05-26
US20190106423A1 (en) 2019-04-11
EP3426637A1 (en) 2019-01-16
WO2017156495A8 (en) 2018-09-27
EP3426637A4 (en) 2019-09-18
CN109071455A (zh) 2018-12-21
US10870652B2 (en) 2020-12-22
AU2017230098B2 (en) 2021-03-25
US11306099B1 (en) 2022-04-19
WO2017156495A1 (en) 2017-09-14
MX2018010971A (es) 2019-03-28
NZ745927A (en) 2024-05-31
AU2017230098A1 (en) 2018-09-20
PL3426637T3 (pl) 2022-05-30
CA3017567A1 (en) 2017-09-14
JP2019507793A (ja) 2019-03-22
JP6972002B2 (ja) 2021-11-24
CN115746000A (zh) 2023-03-07
KR102416971B1 (ko) 2022-07-04
MX388026B (es) 2025-03-19

Similar Documents

Publication Publication Date Title
CN109071455B (zh) 用于调节布鲁顿酪氨酸激酶的化合物及方法
US12227484B2 (en) Inhibitors of PARG
CN110099684B (zh) 用于调节白介素-2诱导性t细胞激酶的化合物和方法
CN105492437B (zh) 取代的苯并呋喃基和苯并噁唑基化合物及其用途
CN110183422B (zh) 核转运调节剂及其用途
CN109890820B (zh) 用作神经营养因子酪氨酸激酶受体抑制剂的氨基吡唑并嘧啶化合物
CN108430978B (zh) 3-羟基-喹唑啉-2,4-二酮衍生物及其作为核酸酶调节剂的用途
CN112574255A (zh) 一类基于有机胂的cdk抑制剂及其制备方法和用途
CN101925595A (zh) 酞嗪酮衍生物
EA032488B1 (ru) Соединения 5-хлор-дифторметоксифенилпиразолопиримидина, представляющие собой ингибиторы янус-киназы
WO2010126960A1 (en) Pyrrolotriazine compounds
JP7120549B2 (ja) Ｔｒｅｋ（ｔｗｉｋ関連ｋチャネル）チャネルのアクチベータ
CN114907338B (zh) 含氮多环稠环类化合物，其药物组合物、制备方法和用途
CN111704615A (zh) 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂
CN115335039A (zh) 胱天蛋白酶6抑制剂和其用途
WO2013107333A1 (zh) 哌嗪基嘧啶类衍生物及其制备方法和用途
HK1262897B (en) Compounds and methods for modulating bruton's tyrosine kinase
HK1262897A1 (en) Compounds and methods for modulating bruton's tyrosine kinase
CN109952104A (zh) 二硫etp衍生物
CA3017567C (en) Compounds and methods for modulating bruton's tyrosine kinase
WO2023239846A1 (en) Heterocyclic compounds as pi3kα inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210127

Address after: England group

Applicant after: Corworth biopharmaceutical Co.,Ltd.

Address before: California, USA

Applicant before: CORVUS PHARMACEUTICALS, Inc.

Effective date of registration: 20210127

Address after: Room 1106, building 8, no.778, Asia Pacific Road, Daqiao Town, Nanhu District, Jiaxing City, Zhejiang Province

Applicant after: Jiaxing Heji Pharmaceutical Co.,Ltd.

Address before: England group

Applicant before: Corworth biopharmaceutical Co.,Ltd.

GR01 Patent grant
GR01 Patent grant